LEADS BIOLABS-B

9887
32.5202.22% ( -0.740 )
Delay Trading: Nov 17, 11:02:00

Profile

About

LEADS BIOLABS-B
LEADS BIOLABS-B
09887.HK

Nanjing Leads Biolabs Co., Ltd., a clinical-stage biotechnology company, engages in the research, development, and commercialization of novel antibody drugs worldwide. It develops therapies in oncology, autoimmune, and other severe diseases. The company’s lead product LBL-024, a PD-L1/4-1BB bispecific antibody for extra-pulmonary neuroendocrine carcinoma; LBL-007, a novel anti-LAG-3 antibody designed to restore T-cell activity; LBL-034, a novel GPRC5D-targeting T-cell engager for anti-tumor activity. In addition, it develops LeadsBody platform, a portfolio of CD3 T-cell engagers that demonstrate anti-tumor efficacy and safety in preclinical/clinical studies; X-body platform, a 4-1BB/PD-L1 bispecific antibody.

Profile

Company Name
Nanjing Leads Biolabs Co., Ltd.
Market
SEHK
Founded
Industry
--
Fiscal Year End
December 31

Related Securities

Industry

Management